Clearmind Medicine Inc. (NASDAQ:CMND) Stock Short Interest Report for October

Clearmind Medicine Inc. (NASDAQ:CMND) saw a significant decrease in short interest in October. As of October 15th, there was short interest totaling 3,861 shares, a decrease of 73.9% from the September 30th total of 14,819 shares. Based on an average daily volume of 35,857 shares, the short-interest ratio is presently 0.1 days. Approximately 0.8% of the shares of the stock are sold short.

Clearmind Medicine Trading Up 0.9%

NASDAQ CMND traded up $0.05 during trading hours on Friday, hitting $5.90. 2,963 shares of the company’s stock were exchanged, compared to its average volume of 110,690. Clearmind Medicine has a 12-month low of $5.25 and a 12-month high of $2,688.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.31 and a current ratio of 4.31. The business’s 50 day moving average is $8.24 and its 200-day moving average is $50.16. The firm has a market capitalization of $3.01 million, a P/E ratio of -0.02 and a beta of 0.93.

Clearmind Medicine (NASDAQ:CMND) last posted its earnings results on Thursday, September 10th. The company reported ($4.56) earnings per share (EPS) for the quarter.

About Clearmind Medicine

Clearmind Medicine Inc (NASDAQ: CMND) is a clinical-stage biotechnology company focused on discovering and developing psychedelic-derived therapeutics for underserved health conditions. The company’s research combines medicinal chemistry with the study of psychoactive compounds to identify treatments designed to address substance-use disorders and other metabolic or behavioral conditions.

Clearmind’s lead investigational compound is MEAI, also known as 5-methoxy-2-aminoindane. The company has evaluated MEAI in preclinical and early clinical research for potential applications including alcohol use disorder and binge drinking.